Fujifilm Diosynth breaks ground on biologics facility

By The Science Advisory Board staff writers

August 19, 2020 -- Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas.

The $55 million, 60,000-sq-ft facility is being constructed in College Station and will house dedicated process development and innovation laboratories. The labs will have biosafety level 2 capabilities with advanced upstream, downstream, and analytical development technologies. The building is part of a 22-acre parcel acquired by Fujifilm in June 2020.

The facility will triple the company's advanced therapies and process development capabilities and help the company provide end-to-end gene therapy solutions from preclinical to commercial launch. It is expected to be operational in the fall of 2021.

Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's...
Fujifilm Diosynth partners with Oxgene for gene therapy
Fujifilm Diosynth Biotechnologies has partnered with Oxgene to deliver gene therapy products with a 25% reduction in production time, the company reported...
Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia
Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support...

Copyright © 2020 scienceboard.net


Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter